Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/11—Aldehydes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/06—Antimigraine agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/32—Alcohol-abuse
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/34—Tobacco-abuse
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/36—Opioid-abuse
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention relates to the use of an extract of Eucalyptus for the preparation of a medicament or a food supplement for the treatment and / or prevention of diseases or pathologies resulting from a disorder of the recapture of neuromediators dopamine, serotonin and / or norepinephrine.
• said extract is enriched in at least 1 of the compounds of formula (I) or any of its diastereoisomeric forms:
• R2 represents an isobutyl group, isobutyl ⁇ -or ⁇ -isobutyl.
• the present invention also relates to the use of at least 1 of the compounds of formula (I) above for the preparation of a medicament or dietary supplement for the treatment and / or prevention of diseases or pathologies arising from a disorder of recapture of said neuromediators.
• Eucalyptus belong to the family Myrtaceae and find the origin of their name in the characteristic shape of their flowers. Indeed, the word Eucalyptus means "well covered” alluding to the operculum (formed of welded petals) styling stamens of flowers. These are generally tall and tall trees that can reach 80 to 100 m in their home country (Australia), from 3 to 20 m in more temperate climates. Their bark, smooth, is detached in long bands of pale to greyish color. They are usually characterized by leaf dimorphism.
• the young leaves are oval-oblong, glaucous green, circled in blue, hugging and sessile while the older leaves are sickle-shaped, greyish green, pendulous, petiole twisted and vertically oriented (equivalence of both sides).
• the flower buds are formed of a chalice, in the form of a quadrangular pyramid, capped with a lid that rises during flowering, revealing numerous stamens with long white filaments and yellow anthers.
• Fruits are 2 to 2.5 cm in diameter capsules with black or brown seeds.
• three species are mainly used in the European pharmacopoeia: Eucalyptus globulus Labill, YE.
• Eucalyptus leaves are traditionally used orally and locally to treat conditions of the respiratory system (bronchitis, inflammation of the throat, stuffy nose, cold ...) or in application to treat injuries, skin ulcers. ..
• Eucalyptus essential oil and eucalyptol (or 1,8-cineole) are used in many preparations to treat respiratory diseases because of their antiseptic, mucolytic and expectorant activities.
• the essential oil is used as a repellent and in veterinary medicine.
• Eucalyptus essential oil The known pharmacological properties of Eucalyptus essential oil are to date: antimicrobial, expectorant and bicicidal properties (WICHTL M. and ANTON R., 1999 - Therapeutic Plants - 177-179), anti-inflammatory and anti-asthmatic (JUERGENS et al, 2003 - Anti-inflammatory activity of 1,8-cineol (eucalyptol) in bronchial asthma: double-bind placebo controlled trial - Respir Med., 97 (3), 250- 256), anti-diabetic (SWANSTON et al, 1990 - Traditional plant treatments for diabetes, Studies in normal and streptozotocin diabetics rats - Diabetologia, 33 (8), 462-464), antihistamines (IKAWATI Z.
• the Applicant has demonstrated the use of an extract of Eucalyptus for the preparation of a drug or dietary supplement for the treatment and / or prevention of diseases or pathologies arising from a disorder recapture of neuromediators.
• the field of the present invention is therefore an Eucalyptus extract for which valuable pharmacological properties have been observed and thus new therapeutic uses envisaged.
• the present invention does not relate to the essential oil of Eucalyptus as such, for which an abundant bibliography had been found.
• the drug or dietary supplement is intended to treat and / or prevent pathologies, resulting from a disorder of the recapture of neuromediators, chosen from the group:
• the treatment and / or prevention of said diseases or pathologies consists of an inhibition of the reuptake of neuromediators.
• neuromediators means dopamine and / or serotonin and / or norepinephrine.
• Eucalyptus is intended to mean the species preferably belonging to the subgenus Eudesmia, Symphomyrtus and Corymbia and more particularly the following species: Eucalyptus glohulus L., Eucalyptus pulverulenta Sims, Eucalyptus kartzoffiana LAS Johnson 1 Blaxell, Eucalyptus macrocarpa Hook., Eucalyptus cinerea F.
• the Eucalyptus extract is obtained from the leaves, flowers, fruits, stems or trunk of Eucalyptus; and preferentially Eucalyptus leaves.
• the Eucalyptus extract used according to the present invention is characterized in that it comprises at least one compound of formula (I) or any of its diastereoisomeric forms.
• Said formula (I) includes among others 4 compounds of the macrocarpal family; these are: macrocarpal A: (5 - ((1R) -1 - ((11S, 7R) -7-hydroxy-3,3,7,11-tetramethyltricyclo (6.3.0.0 (2,4)) undec-11-yl) -3-methylbutyl) -2,4,6-trihydroxybenzene-1,3-dicarbaldehyde) in which R1 forms with the carbon to which
• group R 2 represents a ⁇ -isobutyl
• the mass fraction of macrocarpal A in the Eucalyptus extract according to the present invention is greater than or equal to 0.1% and strictly less than 3%.
• R2 represents an ⁇ -isobutyl
• the mass fraction of macrocarpal B in the Eucalyptus extract according to the present invention is greater than or equal to 0.1% and strictly less than 3% .
• the mass fraction of macrocarpal C in the Eucalyptus extract according to the present invention is greater than or equal to 0.1% and strictly less than 3%.
• the mass fraction of macrocarpal G in the Eucalyptus extract according to the present invention is greater than or equal to 0.1% and strictly less than 5% .
• Said extract of Eucalyptus is obtained by an extraction process made from conventional steps known to those skilled in the art.
• the leaves, flowers, fruits, stems or trunk of Eucalyptus (Eucalyptus sp.) Or a mixture of these parts are crushed and then extracted with an organic solvent which may be an alkane (pentane, hexane, heptane, octane, cyclohexane ), an ether oxide (tetrahydrofuran, dioxane, diethyl ether), an ester (ethyl acetate, isopropyl acetate), an alcohol (methanol, ethanol, propanol, isopropanol, butanol, octanol), a ketone (methyl ethyl ketone, methyl isobutyl ketone). ), a halogenated hydrocarbon (chloroform, dichloromethane) or a mixture of water and
• the extraction is carried out in a plant / solvent ratio of between about 1/1 and about 1/20 and can be repeated 2 to 3 times.
• the temperature of the extraction solvent may be equal to ambient temperature or higher, up to the boiling temperature of the solvent involved.
• the contact time of the plant with the solvent is from about 30 minutes to about 72 hours.
• a solid / liquid separation is then carried out, the plant being separated from the solvent by filtration or centrifugation.
• the filtrate obtained can either be dried directly by total evaporation of the extraction solvent and constitute the final extract; be more or less concentrated.
• a mixed extraction solvent hydro-alcoholic mixture for example
• the concentration continues until evaporation of the organic solvent present.
• a quantity of water is added to the concentrate obtained.
• a liquid-liquid purification step is carried out by adding to the aqueous phase an immiscible solvent which may be an alkane (hexane for example), an ether ether (diethyl ether for example), an ester (ethyl acetate by for example), an alcohol (butanol for example), a ketone (methyl ethyl ketone for example) or a halogenated hydrocarbon (chloroform for example).
• an immiscible solvent which may be an alkane (hexane for example), an ether ether (diethyl ether for example), an ester (ethyl acetate by for example), an alcohol (butanol for example), a ketone (methyl ethyl ketone for example) or a halogenated hydrocarbon (chloroform for example).
• an immiscible solvent which may be an alkane (hexane for example), an ether ether (diethyl ether for example),
• Drying of the final extract is carried out by lyophilization or by more conventional drying means known to those skilled in the art (nebulization, oven, etc.).
• the drying temperatures do not exceed about 60 ° C.
• the extract may be stabilized by addition of an antioxidant such as ascorbic acid, citric acid in amounts of between about 0.05 and about 1 g per 100 g of solids.
• a most remarkable point of the present invention lies in the fact that the pharmacological properties of inhibition of the reuptake of the neuromediators of the extract of Eucalyptus are all the more interesting that said extract is enriched in at least 1 of the compounds of formula (I) or any of its diastereoisomeric forms.
• said Eucalyptus extract is preferably enriched in at least 1 compound of the formula (I).
• Eucalyptus extract enriched in macrocarpal A means an extract of Eucalyptus whose macrocarpal A mass fraction is greater than or equal to 3% and strictly less than 90%, preferably greater than or equal to at 3% and less than 50%, more preferably greater than or equal to 3% and less than 40% and even more preferably greater than or equal to 3% and less than 20%.
• Eucalyptus extract enriched in macrocarpal B means an extract of Eucalyptus whose mass fraction in macrocarpal B superior or equal to 3% and strictly less than 90%, preferably greater than or equal to 3% and less than 50%, more preferably greater than or equal to 3% and less than 40% and even more preferably greater than or equal to 3% and lower at 20%.
• Eucalyptus extract enriched in macrocarpal C means an extract of eucalyptus whose mass fraction in macrocarpal C is greater than or equal to 3% and strictly less than 90%, preferably greater than or equal to at 3% and less than 50%, more preferably greater than or equal to 3% and less than 40% and even more preferably greater than or equal to 3% and less than 20%.
• Eucalyptus extract enriched in macrocarpal G means an extract of Eucalyptus whose macrocarpal G mass fraction is greater than or equal to 5% and strictly less than 90%, preferably greater than or equal to at 5% and less than 50%, more preferably greater than or equal to 5% and less than 40% and even more preferably greater than or equal to 5% and less than 20%.
• the Applicant has shown the influence of an Eucalyptus extract on the reuptake of dopamine and / or norepinephrine and / or serotonin.
• said extract is particularly useful for the preparation of a medicament or dietary supplement intended to treat and / or prevent numerous conditions or pathologies resulting from a dopamine defect. and / or serotonin and / or norepinephrine.
• a dopamine defect and / or serotonin and / or norepinephrine.
• - neurological diseases, conditions or disorders such as neurodegenerative diseases (Alzheimer's disease, Huntington's chorea, Parkinson's disease, stroke, head trauma), amyotrophic lateral sclerosis, senile dementia, frontotemporal dementia , vascular dementia, migraine, neuropathic pain of central origin;
• - psychiatric diseases, conditions or disorders such as depression (endogenous, resistant, reactive or iatrogenic), depressive state, schizophrenia, bipolar disorder, generalized anxiety, stress-related illnesses, panic attacks , obsessive-compulsive disorder, post-traumatic stress disorder, attention deficit and hyperactivity disorder, eating disorders (including bulimia, anorexia), phobia (including agoraphobia), autism;
• somatic disorders such as chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome, gastroesophageal reflux, loss of libido, erectile dysfunction, urinary incontinence.
• the drug or the food supplement according to the invention is advantageously intended to induce withdrawal from nicotine, alcohol, opiates, cannabinoids, psychostimulants and prevent relapse in abstinent subjects.
• the drug or the food supplement according to the invention is advantageously used as a substitution treatment for addictive substances and for preventing and / or treating depressive syndrome associated with withdrawal.
• the Applicant here specifies, in a non-restrictive manner, a few Bibliographical references that recall the link between pathologies and their treatment using a triple dopamine and / or serotonin and / or norepinephrine reuptake inhibitor. An example of each "group" was noted.
• the Eucalyptus extract according to the present invention can therefore be advantageously used in the treatment of these neurological diseases.
• Depression is a common pathology of mood, characterized by feelings of intense sadness, pessimistic thoughts, self-deprecation, often accompanied by loss of drive, enthusiasm and libido.
• the inability to feel pleasure from normally pleasant experiences, also known as anhedonia, is also considered a common symptom in depression.
• Depression is currently treated with selective serotonin reuptake inhibitors such as fluoxetine, citalopram or paroxetine, selective norepinephrine reuptake inhibitors such as reboxetine, or mixed serotonin and norepinephrine reuptake inhibitors such as milnacipran. or venlafaxine.
• Functional disorders also called somatotropic disorders, are disorders that concern the major physiological functions, and that would not be due to organic lesions but to the way organs function (liver, heart ). Functional somatic disorders may be the cause of later disease.
• flbromyalgia is a disorder associating diffuse pain or localized, chronic fatigue, depressive symptoms, memory and concentration problems (DS Rooks, Curr Opin Rheumatol 2007, 19, 111).
• the symptoms of fibromyalgia are treated with mixed norepinephrine / serotonin reuptake inhibitors (Vitton O., Hum Psychopharmacol 2004, 19 Suppl 1: S27).
• the addition of a component promoting dopaminergic tone, as in Eucalyptus extract according to the present invention is advantageous for the preparation of a drug or dietary supplement for treating and / or preventing somatic functional disorders.
• said medicament is in an oral or injectable form.
• the oral form is chosen from the group consisting of a tablet, capsule, capsule, liquid preparations such as syrups, oral solutions or powders for oral suspensions.
• said dietary supplement (or nutraceutical or dietary) is packaged in the form of doses, namely the forms of presentation such as capsules, lozenges, tablets, pills and other similar forms, as well as powder sachets. , ampoules of liquid, vials with droppers and other similar forms of liquid or powder preparations intended to be taken in measured units of small quantities.
• results obtained from an extract of Eucalyptus enriched in at least one compound of formula (I) or any of its diastereoisomeric forms according to the present invention show that the benefits of the present invention can be extended to any composition based on at least one compound of formula (I) or any of its diastereoisomeric forms, whether it is obtained chemically, biochemically or from a plant extract.
• the present invention therefore also relates to the use of at least one compound of formula (I) or any of its diastereoisomeric forms for the preparation of a medicament or dietary supplement for the treatment and / or prevention of diseases or neurological, psychiatric and related disorders, functional somatic syndromes and addictive substance dependence arising from a disorder of neurotransmitter recapture.
• the treatment and / or prevention of said diseases or pathologies consists of an inhibition of the reuptake of neuromediators. Due to its pharmacological properties as a reuptake inhibitor of these neuromediators, the compounds of formula (I) and its diastereomeric forms are particularly useful for the preparation of a medicament or dietary supplement intended to treat and / or prevent numerous affections. or pathologies resulting from a deficiency of dopamine and / or serotonin and / or norepinephrine.
• neurodegenerative diseases Alzheimer's disease, Huntington's chorea, Parkinson's disease, stroke, head trauma
• amyotrophic lateral sclerosis senile dementia
• frontotemporal dementia vascular dementia
• migraine neuropathic pain of central origin.
• - psychiatric diseases, conditions or disorders such as depression (endogenous, resistant, reactive or iatrogenic), depressive state, schizophrenia, bipolar disorder, generalized anxiety, stress-related illnesses, panic attacks obsessive-compulsive disorders, post-traumatic stress disorder, attention deficit and hyperactivity disorder, eating disorders (including bulimia, anorexia), phobia (including agoraphobia), autism;
• somatic disorders such as chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome, gastroesophageal reflux, loss of libido, erectile dysfunction, urinary incontinence.
• the drug or the food supplement according to the invention is advantageously intended to induce withdrawal from nicotine, alcohol, opiates, cannabinoids, psychostimulants and prevent relapse in abstinent subjects.
• the drug or the food supplement according to the invention is advantageously used as a substitution treatment for addictive substances and for preventing and / or treating depressive syndrome associated with withdrawal.
• the present invention relates to the use of Macrocarpal A, Macrocarpal B, Macrocarpal C and / or Macrocarpal G for the preparation of a medicament or dietary supplement for the treatment and / or prevention of neurological conditions or pathologies. , psychiatric and related disorders, functional somatic syndromes and addictive substance dependence arising from a dopamine reuptake disorder and / or serotonin and / or norepinephrine.
• said medicament is in an oral or injectable form.
• the compounds of formula (I) and its diastereoisomeric forms according to the present invention can be obtained by purification of a plant extract or by chemical or biochemical synthesis as described in Total Synthesis of (-) - Macrocarpal C.
• Said compounds can be isolated from "the eucalyptus extract” or "the extract enriched in at least one macrocarpal of formula (I)".
• the techniques for its purification are conventional chromatographic techniques for the skilled person.
• the extracts were fractionated on preparative column having as stationary phase a reversed phase, preferably Symetry Shield ®, 5 .mu.m (Waters) and mobile phase, acetonitrile / water / trifluoroacetic acid in the proportions 95/5 / 0.1%.
• the purity of the compound of formula (I) of such a fraction is greater than or equal to 90%.
• the purity of macrocarpal A, macrocarpal B, macrocarpal C and / or macrocarpal G of such a fraction is greater than or equal to 90%.
• macrocarpal A and / or macrocarpal B and / or macrocarpal C and / or macrocarpal G are used for the preparation of a medicament or food supplement for treating and / or prevent overweight or obesity.
• the present invention also relates to an extract enriched with Eucalyptus characterized in that it contains at least 1 compound of formula (I) or any of its diastereoisomeric forms:
• R1 forms with the carbon to which it is attached a group
• ⁇ CH 3 ⁇ CH 3 cC CH 3 C CH 2
• a 0H group, 0H or 0H and R2 represents an isobutyl group, ⁇ -isobutyl or ⁇ -isobutyl, and in that the mass fraction of Macrocarpal A is greater than or equal to 3% and strictly less than 90%, preferably greater than or equal to 3% and less than 50%, more preferably greater than or equal to 3% and less than 40% and even more preferably greater than or equal to 3% and less than 20% .
• the mass fraction of macrocarpal B is greater than or equal to 3% and strictly less than 90%, preferably greater than or equal to 3% and less than 50%, more preferably greater than or equal to 3% and less than 40% and even more preferentially greater than or equal to 3% and less than 20%.
• the mass fraction of macrocarpal C is greater than or equal to 3% and strictly less than 90%, preferably greater than or equal to 3% and less than 50%, more preferably greater than or equal to 3% and less than 40% and even more preferably greater than or equal to 3% and less than 20%.
• the mass fraction of macrocarpal G is greater than or equal to 5% and strictly less than 90%, preferably greater than or equal to 5% and less than 50%, more preferably greater than or equal to 5% and less than 40% and even more preferably greater than or equal to 5% and less than 20%.
• the present invention relates to the use of said enriched Eucalyptus extract as a medicament or dietary supplement.
• the present invention finally relates to a process for the preparation of such an extract enriched with Eucalyptus.
• the process for obtaining said extract consists of the following steps: - crushing of leaves and / or flowers and / or fruits and / or stems and / or trunk of Eucalyptus at least one extraction with an organic solvent or a mixture of water and organic solvent (s) miscible (s) water.
• the extraction is carried out in a plant / solvent ratio of between about 1/1 and about 1/20 and can be repeated 2 to 3 times.
• the temperature of the extraction solvent may be equal to ambient temperature or higher, up to the boiling temperature of the solvent involved.
• the contact time of the plant with the solvent is from about 30 minutes to about 72 hours.
• the solvent is selected from the group consisting of an alkane (pentane, hexane, heptane, octane, cyclohexane), an ether oxide
• the extraction solvent is dichloromethane or isopropyl acetate.
• the filtrate is dried and then dissolved in a solvent immiscible with water.
• Solid / liquid separation by techniques known to those skilled in the art.
• one or more liquid-liquid extractions are carried out by adding a base, preferably sodium carbonate (Na 2 CO 3 ).
• the combined basic aqueous phases are acidified by addition of acid, preferably hydrochloric acid (HCl) and then extracted by one to several liquid-liquid extractions carried out with a solvent immiscible with water.
• acidification leads to a pH of about 1.
• the combined organic phases can be dried over sodium sulphate and then concentrated in vacuo at a temperature ranging from room temperature to boiling point.
• the concentrate is dried by conventional drying means (nebulization, oven ...) at temperatures not exceeding 60 ° C. preferably and constitutes the extract enriched in macrocarpal G.
• This extract can be stabilized by the addition of a antioxidant such as ascorbic acid or citric acid in amounts of between 0.05 to 1 g per 100 g of solids.
• the eucalyptus extract or the Eucalyptus extract said "enriched in at least one compound of the formula (I) or any of its diastereoisomeric forms" is also obtained by an extraction process using a supercritical fluid as extraction solvent.
• a supercritical fluid as extraction solvent.
• the leaves, flowers, fruits, stems or trunk of Eucalyptus (Eucalyptus sp.) Or a mixture of these parts are crushed or not, then extracted with a supercritical fluid that may be carbon dioxide.
• a first extraction with supercritical CO2 is carried out under the following conditions: the temperature of the fluid is between about 40 ° C. and about 80 ° C., and preferably between about 40 ° C. and about 60 ° C.; its pressure is between about 80 bar and about 250 bar, and preferably between about 100 bar and about 200 bar; the extraction time is between about 1 hour and about 6 hours; the flow rate of the fluid will be adapted by the skilled person depending on the amount of material to be extracted and the size of the autoclave used.
• the CO2 flow rate used in the process according to the present invention is between 2 to 15 kg / hour, advantageously 8 to 12 kg / hour; * for a quantity of plant between 200 and 1000 grams, preferably about 500 grams, "and for an autoclave with a capacity of between 2 and 10 liters, preferably with a capacity of about 5 liters.
• an organic co-solvent the family of alcohols (including ethanol), ether ethers, esters or a mixture of two or more of these solvents.
• the plant thus extracted can then be subjected to a second extraction optionally.
• the extraction fluid is preferably supercritical CO2 with or without co-solvent.
• the operating conditions are: the temperature of the fluid is between about 40 ° C. and about 80 ° C., and preferably between about 40 ° C. and about 60 ° C.; its pressure is between about 80 bar and about 250 bar, and preferably between about 100 bar and about 200 bar; the flow rate of the fluid is between 2 to 15 kg / hour, advantageously 8 to 12 kg / hour;
• the extraction is carried out in a plant / cosolvent mass ratio of between about 1 / 0.1 and 1/5.
• This second extraction step can be renewed if necessary.
• the extraction time is between about 1 hour and about 3 hours per additional extraction step.
• the resulting extract is then evaporated.
• the final extract is dried by lyophilization or by more conventional drying means known to those skilled in the art (nebulization, oven, ). Preferably, the drying temperatures do not exceed about 60 ° C.
• the extract may be stabilized by addition of an antioxidant such as ascorbic acid, citric acid in amounts of between about 0.05 and about 1 g per 100 g of solids.
• the leaves of Eucalyptus globulus are crushed and then extracted with 5 volumes of ethanol at room temperature.
• the contact time of the plant with the solvent is 48 hours.
• the plant is separated from the solvent by filtration.
• the filtrate obtained is dried under vacuum at a temperature of 60 ° C.
• the extract thus obtained will be used for the in vitro tests presented in Example 5.
• the extract obtained contains about 0.65 g of macrocarpal A, about 0.7 g of macrocarpal
• EXAMPLE 2 Preparation of an extract of Eucalyptus globulus Eucalyptus globulus leaves are ground and then extracted 3 times under reflux with 5 volumes of 50% v / v ethanol. The contact time of the plant with the solvent is about 1 hour. The plant is separated from the solvent by filtration. The filtrate obtained is concentrated to 0.5 volume. The liquid-liquid purification is carried out by adding dichloromethane. Three liquid-liquid extractions are carried out. The organic phases are combined and dried over sodium sulfate. The final extract is dried at 60 ° C. under vacuum.
• the extract obtained contains about 1.3 g of macrocarpal A, about 1.4 g of macrocarpal B, about 0.8 g of macrocarpal C, and about 2 g of macrocarpal G per 100 g of dry extract.
• the leaves of Eucalyptus globulus are crushed and then extracted at reflux 2 times with 5 volumes of ethanol-water mixture 50% v / v for about 1 hour.
• the plant is separated from the solvent by filtration.
• the filtrate obtained is concentrated and then stabilized by the addition of 0.1 g per 100 g of citric acid solids.
• the concentrate is frozen and dried by lyophilization.
• the extract obtained contains approximately 0.3 g of macrocarpal A, approximately 0.35 g of macrocarpal B, approximately 0.2 g of macrocarpal C and approximately 0.5 g of macrocarpal G per 100 g of dry extract.
• Example 4 537 g of Eucalyptus leaves are crushed and placed in an autoclave. They are extracted for 4 hours by supercritical CO2 at 40 ° C., 150 bar, with a flow rate of 10 kg / h.
• the leaves thus extracted are subjected to a second extraction with a supercritical CO2 / ethanol mixture at 150 bar, 50 ° C. 1 volume of ethanol is used per 1 weight of plant. It is thus extracted during 2 h, then the sheets are dried by passing CO 2 alone under the same operating conditions for 30 minutes.
• the principle is as follows: the synapses from rat brains are incubated for 15 min at 37 ° C. with
• the samples are rapidly filtered under vacuum through glass fiber filters (GB / B, Packard) and rinsed twice with ice-cold incubation buffer to remove [ 3 H] -serotonin free.
• the filters are dried and the retained radioactivity is measured by a scintillation counter (Topcount, Packard) using a scintillation cocktail (Microscint O 5 Packard).
• the synaptic medium synaptic medium (synapses of rat striatum) is incubated for 15 min at 37 ° C with 0.1 ⁇ Ci [ 3 H] -DA in the presence or absence (control) of the Eucalyptus gulobulus extract prepared according to Example 1 or GBR 12909 (reference) in the buffer solution (see recapture of serotonin).
• Basal activity is determined by incubating the same mixture for 15 min at 37 ° C in the presence of 10 ⁇ M GBR 12909 to block reuptake.
• the samples are rapidly filtered under vacuum through glass fiber filters (GB / B, Packard) and rinsed twice with ice-cold incubation buffer to remove [ 3 H] -dopamine free.
• the filters are dried and the radioactivity retained is measured by a scintillation counter (Topcount, Packard) using a scintillation cocktail (Microscint O, Packard).
• Basal activity is determined by incubating the same mixture for 20 min at 37 ° C in the presence of 10 ⁇ M protriptylline to block reuptake.
• the samples are rapidly filtered under vacuum through fiberglass filters (GBfB, Packard) and rinsed twice with ice-cold incubation buffer to remove free [ 3 H] -NE.
• the filters are dried and the radioactivity retained is measured by a scintillation counter (Topcount, Packard) using a scintillation cocktail (Microscint O, Packard).
• the results are expressed as a percentage of reuptake inhibition of the neuromediator evaluated (see Table 1).
• Table 1 Evaluation of Eucalyptus globulus leaf extract on the reuptake of serotonin, dopamine and norepinephrine. Significant inhibition of the reuptake of serotonin and dopamine at 10 ⁇ g / ml and the three neurotransmitters at 100 ⁇ g / ml are observed.
• the leaves of Eucalyptus globulus are crushed and then extracted with 5 volumes of dichloromethane. The extraction is carried out twice at reflux for 1 hour. This is followed by filtration under vacuum. The combined filtrates are concentrated to 2 volumes.
• Three liquid-liquid extractions are carried out by adding a volume of sodium carbonate (Na 2 CO 3 ) at 0.1 M.
• the combined basic aqueous phases are acidified by the addition of hydrochloric acid
• the enriched extract is fractionated on a preparative column having as stationary phase a reversed phase Symmetry Shield ®, 5 .mu.m (Waters) and mobile phase, acetonitrile / water / trifluoroacetic acid in the proportions 95/5 / 0.1% .
• the macrocarpal G purity of the fraction obtained is about 97%.
• Table 2 Comparison of the activity of a "macrocarpal G-enriched extract", a “macrocarpal G-free extract” and a macrocarpal G-enriched fraction on serotonin reuptake.
• Example 7 Determination of the 50% inhibitory concentration (IC 50 ) of macrocarpal A, macrocarpal B, macrocarpal C and macrocarpal G on the reuptake of neuromediators compared with that of hyperforin.
• Example 5 The protocols followed are those of Example 5. They were repeated for different concentrations of macrocarpal A, B, C and G and hyperforin.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Addiction (AREA)
• Psychiatry (AREA)
• Epidemiology (AREA)
• Pain & Pain Management (AREA)
• Mycology (AREA)
• Alternative & Traditional Medicine (AREA)
• Microbiology (AREA)
• Medical Informatics (AREA)
• Botany (AREA)
• Biotechnology (AREA)
• Psychology (AREA)
• Endocrinology (AREA)
• Reproductive Health (AREA)
• Gynecology & Obstetrics (AREA)
• Child & Adolescent Psychology (AREA)
• Anesthesiology (AREA)
• Rheumatology (AREA)
• Diabetes (AREA)
• Hospice & Palliative Care (AREA)
• Obesity (AREA)
• Hematology (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=37708427

Family Applications (1)

Country Status (20)

Families Citing this family (10)

Citations (1)

Family Cites Families (9)

• 2006
  • 2006-08-01 FR FR0607201A patent/FR2904557B1/fr not_active Expired - Fee Related
• 2007
  • 2007-07-27 MX MX2009000673A patent/MX2009000673A/es not_active Application Discontinuation
  • 2007-07-27 JP JP2009522297A patent/JP2010500974A/ja active Pending
  • 2007-07-27 CN CNA2007800334763A patent/CN101511378A/zh active Pending
  • 2007-07-27 NZ NZ574429A patent/NZ574429A/en not_active IP Right Cessation
  • 2007-07-27 UA UAA200901761A patent/UA99598C2/ru unknown
  • 2007-07-27 CA CA002659162A patent/CA2659162A1/fr not_active Abandoned
  • 2007-07-27 AU AU2007283529A patent/AU2007283529A1/en not_active Abandoned
  • 2007-07-27 BR BRPI0714863-1A patent/BRPI0714863A2/pt not_active IP Right Cessation
  • 2007-07-27 WO PCT/FR2007/001309 patent/WO2008017752A2/fr active Application Filing
  • 2007-07-27 RU RU2009107166/15A patent/RU2445112C2/ru not_active IP Right Cessation
  • 2007-07-27 US US12/309,754 patent/US20090324754A1/en not_active Abandoned
  • 2007-07-27 KR KR1020097004185A patent/KR20090034401A/ko not_active Application Discontinuation
  • 2007-07-27 EP EP07823364A patent/EP2049133A2/fr not_active Withdrawn
  • 2007-07-31 TW TW096127881A patent/TW200820961A/zh unknown
  • 2007-08-01 AR ARP070103382A patent/AR062165A1/es not_active Application Discontinuation
• 2009
  • 2009-01-19 TN TN2009000018A patent/TN2009000018A1/fr unknown
  • 2009-01-20 MA MA31575A patent/MA30592B1/fr unknown
  • 2009-01-29 IL IL196788A patent/IL196788A0/en unknown
  • 2009-03-02 NO NO20090951A patent/NO20090951L/no not_active Application Discontinuation

Patent Citations (1)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events